SynthesisBMC infectious diseases2026
Resistance of different antimicrobials to CRKP: a meta analysis.
Synthesis in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveThis meta-analysis aimed to systematically compare the resistance rates of penicillins, cephalosporins, and carbapenems between carbapenem-resistant Klebsiella pneumoniae (CRKP) and carbapenem-susceptible K. pneumoniae (CSKP) isolates, in order to provide an evidence-based reference for clinical practice.
methodsA systematic literature search was conducted in CNKI, Wanfang, VIP, PubMed, Wiley, and Web of Science databases for studies published from inception to November 2024. Thirteen studies involving 4,883 patients were included. The primary outcome was the resistance rate. Data were pooled using RevMan 5.3 software. Heterogeneity was assessed using the I² statistic, and effect sizes were calculated as risk ratios (RR) with 95% confidence intervals (CIs) using random- or fixed-effects models. Publication bias was evaluated using funnel plots and Egger’s test.
resultsThe pooled analysis revealed that CRKP exhibited significantly higher resistance rates than CSKP to penicillins (RR = 2.74, 95% CI: 1.16–4.32), cephalosporins (ceftazidime: RR = 2.71, 95% CI: 0.89–4.52; cefepime: RR = 2.46, 95% CI: 1.03–3.88; cefuroxime: RR = 3.06, 95% CI: 1.36–4.75), and carbapenems (imipenem: RR = 5.52, 95% CI: 2.59–8.45; meropenem: RR = 5.33, 95% CI: 1.88–8.77).
conclusionCRKP demonstrates significantly higher resistance to β-lactam antibiotics, including penicillins, cephalosporins, and carbapenems, compared to CSKP. These findings underscore the necessity for enhanced resistance monitoring of CRKP infections and the exploration of novel therapeutic strategies. Future studies are warranted to validate these findings and to establish clearer clinical guidelines. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.